Client of a consultant lobbyist
Centre for Commercialization of Regenerative Medicine
- Meetings this Parliament
- 5
- With MPs
- 0
- Since Nov 2021
- 5
- Active registrations
- 1
Most recent reported meeting: Sep 9, 2026.
Lobbying by Centre for Commercialization of Regenerative Medicine: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since Sep 9, 2026 Receives government funding
Consultant Vanessa Lamarre of Sussex Strategy Group
Consultant lobbyists
- Vanessa Lamarre
Institutions they may lobby: Business Development Bank of Canada (BDC), Export Development Canada (EDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), National Defence (DND), National Research Council (NRC), Prime Minister's Office (PMO), Privy Council Office (PCO), Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (1)Hide details
- Discussions with federal officials to seek funding support for the growth and international expansion of Canada's cell and gene therapy and regenerative medicine sector, including potential federal investment to scale domestic biomanufacturing capacity, strengthen supply chain resilience for critical medicines, and support Canada's continued leadership in advanced therapies research, development, and commercialization.
Registration 951874-387413-2. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Vanessa Lamarre · Consultant
- Julie Harb · Policy Advisor, Prime Minister's Office (PMO)
Discussions with federal officials to seek funding support for the growth and international expansion of Canada's cell and gene therapy and regenerative medicine sector, including potential federal investment to scale domestic biomanufacturing capacity, strengthen supply chain resilience for critical medicines, and support Canada's continued leadership in advanced therapies research, development, and commercialization. Read more
-
Reported by Vanessa Lamarre · Consultant
- Greg Reade · Assistant Secretary to the Cabinet, Economic Regional Development Policy, Privy Council Office (PCO)
Discussions with federal officials to seek funding support for the growth and international expansion of Canada's cell and gene therapy and regenerative medicine sector, including potential federal investment to scale domestic biomanufacturing capacity, strengthen supply chain resilience for critical medicines, and support Canada's continued leadership in advanced therapies research, development, and commercialization. Read more
-
Reported by Vanessa Lamarre · Consultant
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Discussions with federal officials to seek funding support for the growth and international expansion of Canada's cell and gene therapy and regenerative medicine sector, including potential federal investment to scale domestic biomanufacturing capacity, strengthen supply chain resilience for critical medicines, and support Canada's continued leadership in advanced therapies research, development, and commercialization. Read more
-
Reported by Vanessa Lamarre · Consultant
- Jessica Fullerton · Director of Policy, Global Affairs Canada (GAC)
Discussions with federal officials to seek funding support for the growth and international expansion of Canada's cell and gene therapy and regenerative medicine sector, including potential federal investment to scale domestic biomanufacturing capacity, strengthen supply chain resilience for critical medicines, and support Canada's continued leadership in advanced therapies research, development, and commercialization. Read more
-
Reported by Vanessa Lamarre · Consultant
- Nicholas Chesterley · Director General, Finance Canada (FIN)
Discussions with federal officials to seek funding support for the growth and international expansion of Canada's cell and gene therapy and regenerative medicine sector, including potential federal investment to scale domestic biomanufacturing capacity, strengthen supply chain resilience for critical medicines, and support Canada's continued leadership in advanced therapies research, development, and commercialization. Read more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.